MLYS (STOCKS)
Mineralys Therapeutics, Inc. Common Stock
$27.500000
+0.880000 (+3.31%)
Prev close: $26.620000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Jon Congleton
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,236.32M
- Employees
- 51
- P/E (TTM)
- -11.42
- P/B (TTM)
- 3.36
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $15.95M |
| Operating Expenses | $170.60M |
| Research and Development | $132.01M |
| Other Operating Expenses | $38.60M |
| Operating Income/Loss | -$170.60M |
| Income/Loss From Continuing Operations After Tax | -$154.65M |
| Income/Loss From Continuing Operations Before Tax | -$154.65M |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Current | $0.00 |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$154.65M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$154.65M |
| Net Income/Loss Available To Common Stockholders, Basic | -$154.65M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.29 |
| Diluted Earnings Per Share | -$2.29 |
| Basic Average Shares | 67,656,355 |
| Diluted Average Shares | 67,656,355 |
| Assets | $661.81M |
| Current Assets | $661.39M |
| Noncurrent Assets | $420.00K |
| Fixed Assets | $38.00K |
| Other Non-current Assets | $382.00K |
| Liabilities | $15.11M |
| Current Liabilities | $15.11M |
| Accounts Payable | $2.02M |
| Other Current Liabilities | $13.10M |
| Noncurrent Liabilities | $0.00 |
| Equity | $646.69M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $646.69M |
| Liabilities And Equity | $661.81M |
| Net Cash Flow From Operating Activities | -$142.42M |
| Net Cash Flow From Operating Activities, Continuing | -$142.42M |
| Net Cash Flow From Investing Activities | -$389.75M |
| Net Cash Flow From Investing Activities, Continuing | -$389.75M |
| Net Cash Flow From Financing Activities | $591.00M |
| Net Cash Flow From Financing Activities, Continuing | $591.00M |
| Net Cash Flow | $58.83M |
| Net Cash Flow, Continuing | $58.83M |
| Comprehensive Income/Loss | -$154.65M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$154.65M |
| Other Comprehensive Income/Loss | $0.00 |